R-5780 with PD-1 blockers for adults with advanced melanoma and other solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1, open-label study gives an oral probiotic (R-5780) to adults who are already receiving PD-1 pathway checkpoint inhibitors for unresectable stage III/IV melanoma, basal cell carcinoma, squamous cell carcinoma, or other solid tumors refractory to PD-1/L1 therapy. Participants will take R-5780 and provide patient-reported overall well-being while physicians measure tumors by CT or MRI per RECIST v1.1. Blood and stool samples will be collected to measure inflammatory markers and to track fecal levels of the probiotic. The primary focus is safety and tolerability, with exploratory biological readouts on the microbiome and inflammation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* At least 18 years of age to 80
* Ability to provide written informed consent
* Unresectable stage III or stage IV melanoma, basal cell carcinoma, or squamous cell carcinoma as per the American Joint Committee on Cancer 2017 Guidelines (8th Edition) regardless of BRAF mutation status and other solid tumors.
* Refractory to anti-PD (checkpoint Protein on Immune Cells called T cells)-1/L1 therapy per RECIST v1.1 defined as subject who has disease progression after receiving at least two complete cycles of ICI (immune checkpoint inhibitors) therapy or disease progression 6 months from initiation of ICI (immune checkpoint inhibitors) therapy while still on active therapy.
* Life expectancy of greater than 3 months
* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
* Subjects must have evaluable disease by CT (computer tomography) or MRI (magnet resonance imaging) per RECIST 1.1 criteria or clinically apparent disease that the investigator can follow for response.

Exclusion Criteria:

* Any serious medical condition or laboratory abnormality or psychiatric condition or any other significant or unstable concurrent medical illness (in the opinion of the Investigator) would preclude protocol adherence or would make the safety of the study drug difficult to assess
* Treatment with systemic broad-spectrum antibiotics.
* No active viral infections.
* Coexisting severe chronic diseases other than cancer (autoimmunity, inflammatory diseases)
* Secondary gastrointestinal motility disorders
* History of solid organ transplant or bone marrow transplant
* Prior CAR-T (chimeric antigen receptor) or allogeneic cellular therapy
* Ongoing systemic immunosuppressive therapy, with the exclusion of prednisone (10 mg/day)
* Concurrent therapy with any other investigational agent, vaccine, or device
* Pregnant or breastfeeding or planning to conceive or father a child during the trial period
* Subjects with untreated brain metastasis. Treated brain metastasis are permitted if stable
* More than 4 prior systemic therapies
* Other cancer medications during treatment period are not permitted
* Enrollment in other clinical trials.

Where it's running

• Sarah Cannon Research Institute
  Denver, Colorado, United States Recruiting
• Sarah Cannon Research Institute
  Nashville, Tennessee, United States Recruiting

Study contacts

• Study coordinator: Janet Stephens, PhD
• Email: jstephens@risetherapeutics.com
• Phone: 650-417-8556

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• DESCANSO/REST mental health program for Spanish-speaking Latino adults with cancer experiencing depression, insomnia, and fatigue

  This program will test whether a telehealth-delivered DESCANSO/REST intervention can help Spanish-speaking Latino adults with stage I–III solid tumors who are receiving systemic cancer treatment feel less depressed, sleep better, and have less fatigue.

  Recruiting at 8 sites Ponce Medical School Foundation, Inc. · Basking Ridge, New Jersey and 7 other locations · NCT07225088

• Evaluating AD1208 for advanced solid tumors

  This study is testing a new drug called AD1208 to see if it is safe and tolerable for people with advanced solid tumors.

  Recruiting at 3 sites Phase 1/2 Avelos Therapeutics Inc. · Seongnam-si, Gyeonggi-do and 2 other locations · NCT06911333

• Evaluating NKT3964 for Adults with Advanced Solid Tumors

  This study is testing a new drug called NKT3964 to see if it can safely help adults with advanced solid tumors, like ovarian or triple-negative breast cancer, after other treatments have failed.

  Recruiting at 17 sites Phase 1 NiKang Therapeutics, Inc. · Little Rock, Arkansas and 20 other locations · NCT06586957

• Personalized immunotherapy platform for cancer treatment

  This study is testing a new way to identify melanoma and skin cancer patients who might not respond well to immunotherapy by analyzing their tumor samples.

  Recruiting at 3 sites Melanoma Institute Australia · Sydney, New South Wales and 2 other locations · NCT06536257

• Investigating NST-628 Oral Tablets for Patients with Solid Tumors

  This study is testing a new oral medication called NST-628 to see if it can safely help adults with advanced solid tumors that have specific genetic mutations.

  Recruiting at 18 sites Phase 1 Nested Therapeutics, Inc · San Francisco, California and 22 other locations · NCT06326411

• Evaluating mutations in solid tumors using liquid biopsy and genome sequencing

  This study is trying to see if a blood test can find important gene changes in patients with advanced solid tumors to help doctors choose the best treatments for them.

  Recruiting Centro di Riferimento Oncologico - Aviano · Aviano, Pordonone · NCT06028724

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.